Comorbidities• Diabetes mellitus (OR: 1.15; 95% CI: 1.01–1.31; P = .030)• CKD (OR: 1.54; 95% CI: 1.34–1.76; P < .001)AKI severity: AKI stage 1 (OR: 2.15; 95% CI: 1.71–2.70; P < .001), AKI stage 2/3 (OR: 2.13; 95% CI: 1.62–2.82; P < .001)Laboratory values• Hemoglobin <10 g/dl (OR: 1.46; 95% CI: 1.27–1.68; P < .001)• Albumin <3.5 g/dl (OR: 1.48; 95% CI: 1.30–1.68; P < .001)• BNP per 100 pg/ml (OR: 1.01; 95% CI: 1.002–1.01; P = .010)Medication• Inotropes (OR: 1.28; 95% CI: 1.11–1.48; P = .001)• IV furosemide use/cumulative dosage per 10 mg (OR: 1.04; 95% CI: 1.03–1.06; P < .001). This evidence concerns the gene NPPB and diabetes mellitus.